Phase II trial of irinotecan base regimen of bevacizumab for metastatic colorectal cancer progressed on oxaliplatin base regimen of bevacizumab

ABSTRACT: Interventions: Bevacizumab and irrinotecan based chemotherapy (q2w FOLFIRI, q3w XELIRI, q3w/q4w IRIS) Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2625093 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR